GAVIN BAKER: Below-market AI compute contracts repricing higher should lift cloud revenue and may mark the peak of external financing for the buildout

The Gist

Gavin Baker says the labs locked in cheap compute, and now it is worth much more. As old contracts end and prices reset higher, cloud companies earn more, which makes it easier to fund the buildout without so much outside money. This is a steelman: Gavin Baker's thread is reconstructed in its strongest fair form, not endorsed.

Conclusion

Repricing of below-market compute contracts should accelerate cloud and neocloud revenue and ease financing concerns, so external financing as a share of the AI buildout may be near its peak.

Premises

1. Most compute contracts signed by OpenAI and Anthropic in 2024 to early 2026 are now priced well below spot.
2. OpenAI's CFO said compute it bought a year earlier could be sold for three to five times its cost.
3. If either lab disappeared, its contracts would likely be assumed at higher prices by others.
4. As those contracts roll off and reprice to market, cloud and neocloud revenue growth should accelerate.
5. Analysis he cites from 3Fourteen Research shows B200 clusters earning about a 37 percent IRR even if rental prices fell 40 percent a year, and returns at that level attract funding.

Assumptions

• The 3Fourteen Research model was not publicly available; Baker suggested the firm share it, and public models with milder price declines show lower returns of about 21 to 29 percent.
• Credit markets showed strain in 2026, including CoreWeave credit default swaps near 855 basis points in late July and record hyperscaler and chipmaker spreads later.
• The CFO remark concerned compute bought a year earlier; OpenAI describes committing capital in tranches against demand.

Analysis

Argument type: Inductive.

Potential Fallacies

• Non sequitur (revenue to financing share) (Inference from P4/P5 to the conclusion) — Higher provider revenue and attractive returns do not by themselves show that external financing as a share of the buildout has peaked. Attractive returns usually draw more external capital. The share also depends on capex growth, internal cash flow and credit conditions, none of which the premises address.
• Hasty generalization (P1, P2 to P4 and the conclusion) — A claim about two labs' contracts and one CFO remark about compute bought a year earlier (which A3 notes was bought in tranches against demand) is extended to the whole contract book. It is then extended to sector-wide cloud revenue and to the financing of the whole buildout.
• Treating a current price as a durable one (P1, P4) — The spot-versus-contract gap reflects present scarcity. Higher prices and returns attract new capacity and new chip generations, which can erode the gap before contracts roll off. P5's own 40% annual price-decline scenario concedes that prices move.
• Unsupported counterfactual / circularity (P3) — P3 assumes other buyers would assume a failed lab's contracts at higher prices. A lab failure would likely coincide with weaker demand or tighter credit, which is when replacement bids are weakest. The antecedent undercuts the consequent.
• Reliance on an unverifiable source and selective evidence (P5 (with A1, A2)) — The headline 37% IRR comes from a model that is not public. Public models with milder price declines show 21-29%. The most favorable figure is foregrounded without explaining why it should govern. Funding appetite is also treated as confirming the economics even while credit spreads are wide.
• Level shift / equivocation (P2 vs P1; P5 vs conclusion) — The argument moves between different quantities: resale value relative to cost (P2), contract price relative to spot (P1), project-level IRR (P5), and system-wide financing share (conclusion). No link is given between them, and the absolute versus relative meaning of 'peak' is left open.

Counterarguments

These challenges are not ranked.

• Conclusion (High impact) — Attractive returns historically draw more leveraged capital, not less. Fiber, shipping and shale all saw financing rise as unit economics looked strong, followed by overbuild and compression. Wide credit spreads on heavy issuance look like the late stage of a capex boom, not a peak in external financing.
• Premise 1 (High impact) — Spot is a scarcity price. As new capacity, new chip generations and in-house hyperscaler builds arrive, spot prices fall. Repricing at roll-off would then be toward a falling market, and the contract-to-spot gap would narrow or vanish before it can be captured.
• Premise 4 (High impact) — Providers' repricing gains are the labs' cost increases. OpenAI and Anthropic are loss-making and depend on external capital, so higher compute bills raise their funding needs. Financing demand may shift upstream to the labs, or labs may churn, renegotiate or default, rather than financing easing.
• Premise 4 (Medium impact) — Contracts signed from 2024 to early 2026 are typically multi-year and may not roll off until 2027-2030. Repricing benefits could arrive after near-term refinancing pressure has already peaked or caused damage.
• Premise 5 (Medium impact) — The stated gap between 37% and 21-29% IRRs, together with CoreWeave CDS near 855 bp, suggests the headline return relies on favorable assumptions and that funders already demand large risk premia. Financing may be rationed by credit conditions regardless of modeled IRR.
• Premise 3 (Medium impact) — The scenario in which a lab disappears is one of weak demand and tight credit, so it is correlated with the conditions that would depress, not raise, prices. Lender protection is least reliable exactly when it is needed.
• Conclusion (Medium impact) — The share of external financing could fall simply because cash-rich hyperscalers enlarge the denominator, with no improvement in the fragile neocloud and lab segment. Absolute external financing could keep growing.

Suggested Improvements

• Define and measure 'peak' — Specify whether 'peak' refers to absolute external dollars, share of total capex, or marginal cost of capital. Support it with quarterly data on debt, equity, vendor and private-credit issuance against capex and internal cash flow. The conclusion names a quantity that none of the premises measure. Without this, the claim is neither supported nor testable.
• Contract tenor and roll-off schedule — Provide remaining performance obligations, average contract duration and expiry dates for the below-market contracts, and note any escalators, renewal options or take-or-pay terms. Timing determines whether revenue acceleration arrives before or after financing stress. It is the main link between P1 and P4.
• Verify the IRR evidence — Publish the 3Fourteen model with inputs and sensitivities (utilization, residual value, power and financing costs, useful life), and reconcile it with public 21-29% estimates. The central quantitative support is currently unauditable and in tension with public models.
• Address the supply response and price durability — Add evidence on GPU rental price indices by chip generation, announced capacity additions and Rubin-class ramps, and test repricing under spot declines steeper than 40%. If spot prices mean-revert as supply lands, the repricing premium and the thesis weaken.
• Counterparty ability to pay — Analyze OpenAI and Anthropic revenue growth, burn and fundraising capacity against rising compute costs, and add a net system-wide view of the provider-lab transfer. Repricing is revenue for providers only if the labs can afford it. Otherwise financing strain moves rather than eases.
• Replace the P3 hypothetical — Cite precedents of contract assignment in distressed settings, or drop the claim and instead present downside scenarios in which spot prices fall alongside a lab failure. The current counterfactual is weakest in the scenario it is meant to cover.

Scenario Tests

• Supply catches up with demand through new GPU generations and capacity ramps, so spot prices fall toward or below legacy contract rates. (Challenges) — The contract-to-spot gap closes before repricing can be realized. Revenue acceleration fails and neocloud debt coverage weakens, which worsens the financing picture.
• Spot prices remain elevated and contracts roll off within 12-24 months, with labs paying market rates on rising revenue. (Supports) — Provider revenue and cash flow rise and the narrow repricing thesis holds. Even then, a falling external-financing share needs separate evidence about capex and internal cash flow.
• Improved returns attract a new wave of leveraged capacity, so absolute external financing keeps rising for several quarters despite repricing. (Challenges) — The 'peak' claim is wrong in absolute terms and probably in share terms. This mirrors earlier infrastructure booms in which strong unit economics encouraged more leverage.
• One of the two large labs fails during a funding or demand shock. (Challenges) — Replacement bids at higher prices are unlikely when the shock is also depressing demand and credit. P3 provides little protection, and contagion across neocloud and lender balance sheets becomes the main risk.
• Hyperscaler cash-flow-funded capex grows rapidly while neocloud and lab-linked debt issuance flattens. (Neutral) — The aggregate external-financing share could fall, consistent with the headline. The cause would be the larger denominator and not repricing-driven self-funding, so the mechanism claimed by the argument would still be unproven.
• Credit spreads for neoclouds stay near 2026 stress levels while modeled IRRs remain high. (Challenges) — Funding is limited by counterparty and collateral risk and not by project returns, so the link in P5 from returns to funding availability is weakened.

Coherence & Relevance

The chain from below-market contracts to repricing to revenue acceleration to improved returns is coherent. The step to 'external financing share may be near its peak' is not. That claim needs premises on capex trajectory, internal cash flow, the mix of financing and the timing of roll-offs, and none is given. The stated credit strain also points the other way. The hedged language makes the conclusion compatible with the premises, but the premises justify only a modest, partial version of it.

• Most compute contracts signed by OpenAI and Anthropic in 2024 to early 2026 are now priced well below spot. (Strong) — Directly relevant to the repricing mechanism. Gaps: no pricing data, no roll-off timing, and the assumption that spot persists.
• OpenAI's CFO said compute it bought a year earlier could be sold for three to five times its cost. (Moderate) — Supports the idea that compute is valuable. It measures resale value against cost, not contract price against spot, and covers a narrow set of tranches.
• If either lab disappeared, its contracts would likely be assumed at higher prices by others. (Weak) — Addresses counterparty tail risk, not repricing or financing share, and presupposes the demand conditions it needs to show.
• As those contracts roll off and reprice to market, cloud and neocloud revenue growth should accelerate. (Strong) — Largely derivative of P1. Omits contract tenor, capacity and utilization, customer demand elasticity and the labs' ability to pay.
• Analysis he cites from 3Fourteen Research shows B200 clusters earning about a 37 percent IRR even if rental prices fell 40 percent a year, and returns at that level attract funding. (Moderate) — Relevant to the financeability of clusters. It supports more external capital, not a lower external share, and the model is not public.

View this argument on LogicFirst.ai